Ticlopidine: A new antiplatelet agent for the secondary prevention of stroke

J. C. Murray*, M. A. Kelly, P. B. Gorelick

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Ticlopidine hydrochloride, an inhibitor of platelet aggregation that has been approved for use in the United States for secondary stroke prevention, may be more effective than aspirin for the secondary prevention of stroke, but this advantage decreases greatly over time. The pharmacology, adverse effects, efficacy, drug interactions, and indications for ticlopidine are discussed here with summaries of various clinical trials. The drug is more costly than aspirin, and patients must have complete blood counts during the first 3 months of therapy. It is recommended for those who cannot take aspirin and may be more effective in certain groups-nonwhites, diabetics, and women and those with vertebrobasilar ischemia, intermittent claudication, unstable angina, and nonproliferative retinopathy.

Original languageEnglish (US)
Pages (from-to)23-31
Number of pages9
JournalClinical neuropharmacology
Issue number1
StatePublished - 1994


  • Aspirin
  • Diabetes
  • Ischemia, vertebrobasilar
  • Stroke, secondary
  • Ticlopidine hydrochloride

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Ticlopidine: A new antiplatelet agent for the secondary prevention of stroke'. Together they form a unique fingerprint.

Cite this